LEVODOPACARBIDOPAENTACAPONE MYLAN

Main information

  • Trade name:
  • LEVODOPACARBIDOPAENTACAPONE MYLAN Film-coated tablet 150MG/37,5MG/200MG
  • Dosage:
  • 150MG/37,5MG/200MG
  • Pharmaceutical form:
  • Film-coated tablet
  • Administration route:
  • Oral use
  • Units in package:
  • 100 Tablet container
  • Prescription type:
  • with prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • LEVODOPACARBIDOPAENTACAPONE MYLAN Film-coated tablet 150MG/37,5MG/200MG
    Czech Republic
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • LEVODOPA, AN INHIBITOR OF DEKARBOXYLASY AND COMT INHIBITOR
  • Product summary:
  • LEVODOPA/CARBIDOPA/ENTACAPONE MYLAN

Other information

Status

  • Source:
  • SUKL - Státní ústav pro kontrolu léčiv
  • Authorization status:
  • R - active MA/authorised medicinal product
  • Authorization number:
  • 27/ 008/16-C
  • Authorization date:
  • 12-05-2017
  • EAN code:
  • 8588004913677
  • Last update:
  • 05-04-2018

10-7-2018

Corbilta (Orion Corporation)

Corbilta (Orion Corporation)

Corbilta (Active substance: levodopa / carbidopa / entacapone) - Centralised - Renewal - Commission Decision (2018)4468 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2785/R/15

Europe -DG Health and Food Safety